KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Assets (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Current Assets for 18 consecutive years, with $18.2 billion as the latest value for Q1 2026.

  • For Q1 2026, Current Assets rose 3.63% year-over-year to $18.2 billion; the TTM value through Mar 2026 reached $18.2 billion, up 3.63%, while the annual FY2025 figure was $18.0 billion, 3.42% down from the prior year.
  • Current Assets hit $18.2 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $18.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $19.5 billion in Q4 2023 and bottomed at $14.3 billion in Q1 2022.
  • Average Current Assets over 5 years is $17.5 billion, with a median of $18.0 billion recorded in 2025.
  • Year-over-year, Current Assets soared 42.28% in 2022 and then fell 11.65% in 2025.
  • Regeneron Pharmaceuticals' Current Assets stood at $15.9 billion in 2022, then increased by 22.63% to $19.5 billion in 2023, then dropped by 4.2% to $18.7 billion in 2024, then fell by 3.42% to $18.0 billion in 2025, then grew by 1.04% to $18.2 billion in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $18.2 billion, $18.0 billion, and $18.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.